AS2-10
AS2-10 is a cyclooxygenase-2 (COX-2) inhibitor with an IC50 of 3.6 μM. AS2-10 inhibits COX-2 through hydrogen bonding and electrostatic interactions within the catalytic pocket, and also exhibits inhibitory activity against COX-1. AS2-10 possesses peripheral analgesic and anti-inflammatory effects, alleviating acetic acid-induced writhing, formalin-induced licking responses, and Carrageenan (HY-125474)-induced paw edema. AS2-10 can be used in research related to inflammation and pain.
For research use only. We do not sell to patients.
- Formula: C25H22FNO3
- Molecular Weight:403.45
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
AS2-10 (30 μg/mL; 24-48 h) exhibits low cytotoxicity against normal mouse 3T3 fibroblasts[1].
AS2-10 (0.1-100 mM) inhibits COX-1 and COX-2 with IC50 values of 12.8 and 3.6 μM, and a selectivity index of 3.56[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Murine 3T3 fibroblast cells
-
Concentration:30 μg/mL
-
Incubation Time:24-48 h
-
Result:Produced 8.74% inhibition of cell viability.
In Vivo
AS2-10 (10 mg/kg; i.p.) significantly attenuates both neurogenic (phase I) and inflammatory (phase II) pain responses in the formalin-induced paw licking test[1].
AS2-10 (10 mg/kg; i.p.) significantly inhibits Carrageenan (HY-125474) -induced paw edema in mice, demonstrating notable anti-inflammatory efficacy[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Albino mice (adult, male and female, 6-7 weeks, 25-30 g)[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; single dose
-
Result:Reduced the average number of writhing responses to 22.
-
Animal Model:Albino mice (adult, male and female, 6-7 weeks, 25-30 g)[1]
-
Dosage:10 mg/kg
-
Administration:i.p..; single dose
-
Result:Reduced phase I paw licking/biting time to 23.0 seconds.
Reduced phase II paw licking/biting time to 114.6 seconds.
-
Animal Model:Albino mice (adult, male and female, 6-7 weeks, 25-30 g)[1]
-
Dosage:10 mg/kg
-
Administration:i.p..; single dose
-
Result:Demonstrated a paw thickness of 4.13 mm at 5 h.
Chemical Information
-
Molecular Weight 403.45
-
Formula C25H22FNO3
-
SMILES
O=C(NCC1=CC=C(F)C=C1)COC2=CC=C(C(/C=C/C3=CC=C(C)C=C3)=O)C=C2
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Carrageenan-Induced Paw Edema
Carrageenan-induced paw edema is an acute inflammation model in which intraplantar injection of carrageenan induces localized inflammatory swelling characterized by vascular permeability, leukocyte infiltration, and production of inflammatory mediators such as prostaglandins and cytokines, making it widely used to evaluate anti-inflammatory agents in vivo. The resulting paw volume or thickness increase is quantified over time as a direct readout of inflammatory intensity and drug efficacy, typically reflecting cyclooxygenase-mediated prostaglandin-driven edema formation and immune cell recruitment in peripheral tissue[20].
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)